8 hedge funds and family offices disclose a CVS position in their latest SEC 13F filing — combined $1.13B in market value. Of those, 3 are classified as value investors.
| # | Investor | Fund | Shares | Value | % of Portfolio | Filed |
|---|---|---|---|---|---|---|
| 1 | Christopher Davis | Davis Selected Advisers, LP | 12,239,666 | $879.1M | 4.04% | 2026-03-31 |
| 2 | Prem Watsa | Fairfax Financial Holdings Ltd | 2,712,000 | $194.8M | 10.03% | 2026-03-31 |
| 3 | Ray Dalio | Bridgewater Associates LP | 618,428 | $44.4M | 0.20% | 2026-03-31 |
| 4 | Mark Hillman | Hillman Capital Management Inc | 71,685 | $5.7M | 3.58% | 2025-12-31 |
| 5 | Tweedy Browne | Tweedy Browne Company LLC | 19,132 | $1.4M | 0.11% | 2026-03-31 |
| 6 | Matrix Asset Advisors | Matrix Asset Advisors Inc/NY | 6,175 | $490K | 0.04% | 2025-12-31 |
| 7 | Christopher Bloomstran | Semper Augustus Investments Group LLC | 499 | $40K | 0.01% | 2025-12-31 |
| 8 | Olstein Capital Management | Olstein Capital Management LP | 56,000 | $4K | 0.91% | 2025-12-31 |
As of the latest 13F window, 8 tracked superinvestors hold CVS. The largest disclosed position is Christopher Davis at $879.1M (4.0% of portfolio).
13F filings are due 45 days after each quarter end and capture long-equity positions held by U.S. institutional managers with $100M+ AUM. Use this page to see exactly who is buying CVS, how concentrated each position is, and the implied conviction level relative to the rest of each investor's book.
Key takeaways
8 hedge funds and family offices disclose a CVS position in their latest SEC 13F filing — combined $1.13B in market value. Of those, 3 are classified as value investors.
| # | Investor | Fund | Shares | Value | % of Portfolio | Filed |
|---|---|---|---|---|---|---|
| 1 | Christopher Davis | Davis Selected Advisers, LP | 12,239,666 | $879.1M | 4.04% | 2026-03-31 |
| 2 | Prem Watsa | Fairfax Financial Holdings Ltd | 2,712,000 | $194.8M | 10.03% | 2026-03-31 |
| 3 | Ray Dalio | Bridgewater Associates LP | 618,428 | $44.4M | 0.20% | 2026-03-31 |
| 4 | Mark Hillman | Hillman Capital Management Inc | 71,685 | $5.7M | 3.58% | 2025-12-31 |
| 5 | Tweedy Browne | Tweedy Browne Company LLC | 19,132 | $1.4M | 0.11% | 2026-03-31 |
| 6 | Matrix Asset Advisors | Matrix Asset Advisors Inc/NY | 6,175 | $490K | 0.04% | 2025-12-31 |
| 7 | Christopher Bloomstran | Semper Augustus Investments Group LLC | 499 | $40K | 0.01% | 2025-12-31 |
| 8 | Olstein Capital Management | Olstein Capital Management LP | 56,000 | $4K | 0.91% | 2025-12-31 |
As of the latest 13F window, 8 tracked superinvestors hold CVS. The largest disclosed position is Christopher Davis at $879.1M (4.0% of portfolio).
13F filings are due 45 days after each quarter end and capture long-equity positions held by U.S. institutional managers with $100M+ AUM. Use this page to see exactly who is buying CVS, how concentrated each position is, and the implied conviction level relative to the rest of each investor's book.
Key takeaways
